Anti-GPRC5D CAR-T cells infusion
BG-CT-22-012
Phase 2 mab active
Quick answer
Anti-GPRC5D CAR-T cells infusion for Multiple Myeloma in Relapse is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Multiple Myeloma in Relapse
- Phase
- Phase 2
- Modality
- mab
- Status
- active